Skip to main content
. 2020 Feb 19;15(2):e0227475. doi: 10.1371/journal.pone.0227475

Fig 3.

Fig 3

Comparison of overall survival between TARE and cTACE for hepatocellular carcinoma at 1-year(A), 2-year(B) and 3-year(C).